Abstract:Deposition of beta-amyloid (A beta) fibrils is an early event in the neurodegenerative processes associated with Alzheimer's disease. According to the "amyloid cascade" hypothesis, A beta aggregation, and its subsequent deposition as fibrils, is the underlying cause of disease. A beta is a proteolytic product of amyloid precursor protein (APP); several mutations in APP have been identified that are associated with early onset of disease. Transgenic mice overexpressing APP with the Swedish mutation develop numerous plaques but, surprisingly, lack the neurofibrillary tangles and neuronal loss characteristic of Alzheimer's disease, in apparent contradiction of the amyloid cascade hypothesis. However, recent studies suggest that coproduction of sAPP alpha, an alternative proteolytic product of APP, increases synthesis of transthyretin that, in turn, interacts directly with A beta to inhibit its toxicity. Here we report results from biophysical analysis of A beta aggregation kinetics in the presence of transthryetin. At substoichiometric ratios, transthyretin drastically decreased the rate of aggregation without affecting the fraction of A beta in the aggregate pool. Detailed analysis of the data using a mathematical model demonstrated that the decrease in aggregation rate was due to both a decrease in the rate of elongation relative to the rate of initiation of filaments and a decrease in lateral association of filaments to fibrils. Tryptophan quenching data indicated that transthyretin binds weakly to A beta, with an estimated apparent K-S of 2300 M-1. Taken together, the data support a hypothesis wherein transthyretin preferentially binds to aggregated rather than monomeric A beta and arrests further growth of the aggregates.

Inhibitory Effect of TA9902 on Amyloid Β- Peptide 1 -42 Aggregation by Fourier- Transform Infrared Spectroscopy Study

Molecular Integrative Analysis of the Inhibitory Effects of Dipeptides on Amyloid β Peptide 1–42 Polymerization

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Molecular Hairpin: a Possible Model for Inhibition of Tau Aggregation by Tannic Acid.

Dual Effect of Thioflavin T on the Nucleation Kinetics of Amyloid Β-Protein 40

Tabersonine Inhibits Amyloid Fibril Formation and Cytotoxicity of Aβ(1–42)

Controlled preparation of tannic acid-derived carbonized dots and their use to inhibit amyloid aggregation and promote aggregate disaggregation

A Molecular Integrative Study on the Inhibitory Effects of WRR and ERW on Amyloid Β Peptide (1–42) Polymerization and Cell Toxicity

Thermodynamic Analysis of the Molecular Interactions between Amyloid β-Peptide 42 and (−)-Epigallocatechin-3-gallate

Molecular Integrative Study on Inhibitory Effects of Pentapeptides on Polymerization and Cell Toxicity of Amyloid-β Peptide (1–42)

Antioxidant EGb761 Matched TA9901 Changes Secondary Conformation of Amyloid-Β-peptide1-42 by Circular Dichroism Spectrum

Study of biologic characters of Aβ42 and Aβ42 oligomer

Inhibition Effect and Molecular Mechanisms of Quercetin on the Aβ42 Dimer: A Molecular Dynamics Simulation Study.

Atomistic Characterization of Binding Modes and Affinity of Peptide Inhibitors to Amyloid-Β Protein

Impact of Alternating Amino Acid Sequences on Beta-Amyloid-induced Neurotoxicity and Neuroinflammation in Alzheimer's Disease.

Inhibition Mechanisms of (-)-epigallocatechin-3-gallate and Genistein on Amyloid-beta 42 Peptide of Alzheimer's Disease Via Molecular Simulations

Thermodynamic analysis of the molecular interactions between amyloid beta-peptide 42 and (-)-epigallocatechin-3-gallate.

Kinetic Studies of Inhibition of the Amyloid Beta (1–42) Aggregation Using a Ferrocene-Tagged Β-Sheet Breaker Peptide

Kinetics of Inhibition of Β-Amyloid Aggregation by Transthyretin

Toward the Mode of Action of the Clinical Stage All-d-Enantiomeric Peptide RD2 on Aβ42 Aggregation